Corina Lesseur1, Jia Chen2,3,4,5. 1. Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1057, New York, NY, 10029, USA. 2. Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1057, New York, NY, 10029, USA. Jia.Chen@mssm.edu. 3. Department of Pediatrics, Icahn School of Medicine at Mount Sinai, Box 1057, 1 Gustave Levy Place, New York, NY, 10029, USA. Jia.Chen@mssm.edu. 4. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, Box 1057, 1 Gustave Levy Place, New York, NY, 10029, USA. Jia.Chen@mssm.edu. 5. Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, Box 1057, 1 Gustave Levy Place, New York, NY, 10029, USA. Jia.Chen@mssm.edu.
Abstract
PURPOSE OF REVIEW: Herein, we summarize existent epidemiological studies relating adverse maternal metabolic environments of maternal obesity and gestational diabetes and placental DNA methylation. RECENT FINDINGS: Multiple studies have evaluated associations between intrauterine exposure to gestational diabetes and/or maternal glucose levels and DNA methylation at candidate metabolic genes as well as in epigenome-wide studies. Some of the genomic regions more consistently associated include lipid-related genes (LPL and PPARGC1A), the major histocompatibility complex (MHC), and imprinted genes. Studies solely focused on maternal obesity influences on the placental epigenome are scarce. Understanding the placental mechanisms involved in fetal metabolic programming could lead to discovery of placental biomarkers at birth that predict later-life metabolic risk. Moving forward is important to standardize methods utilized in epigenetics research; consistent methodology can help interpret disparate findings. Larger studies with longitudinal follow-up are needed to address future challenges in fetal programming research.
PURPOSE OF REVIEW: Herein, we summarize existent epidemiological studies relating adverse maternal metabolic environments of maternal obesity and gestational diabetes and placental DNA methylation. RECENT FINDINGS: Multiple studies have evaluated associations between intrauterine exposure to gestational diabetes and/or maternal glucose levels and DNA methylation at candidate metabolic genes as well as in epigenome-wide studies. Some of the genomic regions more consistently associated include lipid-related genes (LPL and PPARGC1A), the major histocompatibility complex (MHC), and imprinted genes. Studies solely focused on maternal obesity influences on the placental epigenome are scarce. Understanding the placental mechanisms involved in fetal metabolic programming could lead to discovery of placental biomarkers at birth that predict later-life metabolic risk. Moving forward is important to standardize methods utilized in epigenetics research; consistent methodology can help interpret disparate findings. Larger studies with longitudinal follow-up are needed to address future challenges in fetal programming research.
Authors: Line Sletner; Aina E F Moen; Chittaranjan S Yajnik; Nadezhda Lekanova; Christine Sommer; Kåre I Birkeland; Anne K Jenum; Yvonne Böttcher Journal: Front Endocrinol (Lausanne) Date: 2021-12-24 Impact factor: 5.555
Authors: Jessica R Zolton; Lindsey A Sjaarda; Sunni L Mumford; Tiffany L Holland; Keewan Kim; Kerry S Flannagan; Samrawit F Yisahak; Stefanie N Hinkle; Matthew T Connell; Mark V White; Neil J Perkins; Robert M Silver; Micah J Hill; Alan H DeCherney; Enrique F Schisterman Journal: F S Rep Date: 2022-01-20
Authors: Teresa E Daniels; Alexander I Sadovnikoff; Kathryn K Ridout; Corina Lesseur; Carmen J Marsit; Audrey R Tyrka Journal: Mol Cell Endocrinol Date: 2020-01-29 Impact factor: 4.102
Authors: Jasmine F Plows; Joanna L Stanley; Philip N Baker; Clare M Reynolds; Mark H Vickers Journal: Int J Mol Sci Date: 2018-10-26 Impact factor: 5.923